Endo Announces Extension Of U.S. Marketing Rights For Voltaren Gel - Quick Facts

(RTTNews) - Endo International plc (ENDP, ENL.TO) announced the extension of its exclusive U.S. marketing rights for the currently marketed prescription medicine Voltaren Gel 1% as well as for the product's Authorized Generic, should Endo opt to commercially launch it in the future. Voltaren Gel is a non-steroidal anti-inflammatory drug used for the relief of joint pain of osteoarthritis in the knees, ankles, feet, elbows, wrists, and hands.

The company, through an indirect subsidiary, has entered into a licensing agreement with Sandoz Inc. and Novartis AG through June 30, 2023. Sandoz will continue to supply the product to Endo. Endo will make additional payments so long as there is no entry of a generic competitor product and the same minimum sales royalties and tiered, double-digit royalties on net sales of Voltaren Gel in the U.S. as the current licensing agreement.

Endo said the company will provide more detail regarding the anticipated financial impact of the license extension on its future performance when the company provides 2016 guidance.